Cardiovascular Business: Pop Goes the Pillbox: Will Polypharmacy Problems Limit the Adoption of SGLT2 Inhibitors?

Many people with heart failure take a dozen or more pills a day to manage their heart condition as well as a range of other comorbidities.

Cardiovascular Business talked to Mikhail Kosiborod, MD, director of cardiometabolic research at Saint Luke’s Mid America Heart Institute and chair of the DEFINE-HF trial, to find out if polypharmacy problems could limit the adoption of SGLT2 inhibitors--the new promising treatment to come of the trial for heart failure and type 2 diabetes.

“If the risk of dying of heart failure is the same as someone with advanced lung cancer, wouldn’t you want them to live longer and have a better quality of life, even if it means being on multiple medications?” Dr. Kosiborod said. "What we absolutely should be doing is examining each patient’s medication list and eliminating those that are nonessential.”

Read the full Cardiovascular Business article: Pop Goes the Pillbox: Will Polypharmacy Problems Limit the Adoption of SGLT2 Inhibitors?

Related Content

hand holding heart-shaped pill
Sep. 17, 2019
TCTMD: DEFINE-HF: Dapagliflozin Improves Function and Quality of Life, but Not Biomarkers, in HFrEF
A new study championed by Saint Luke's, called DEFINE-HF, was recently presented at the Heart Failure Society of America annual meeting. tctMD breaks down this groundbreaking study of the new treatment option with study chair Mikhail Kosiborod, MD.
doctor typing on a computer with graphs on a clipboard
Sep. 16, 2019
DEFINE-HF Trial demonstrates potential early benefits of dapagliflozin on symptoms, physical function and quality of life in patients with heart failure after 12 weeks of treatment
Trial findings shared at HFSA’s Annual Scientific Meeting Late-Breaking Clinical Trial Session

Mikhail N Kosiborod, MD

Cardiology